183 related articles for article (PubMed ID: 34386661)
21. A randomized double-blind cross-over trial to study the effects of resistant starch prebiotic in chronic kidney disease (ReSPECKD).
Shamloo M; Mollard R; Wang H; Kingra K; Tangri N; MacKay D
Trials; 2022 Jan; 23(1):72. PubMed ID: 35073986
[TBL] [Abstract][Full Text] [Related]
22. Protein-bound molecules: a large family with a bad character.
Sirich TL; Meyer TW; Gondouin B; Brunet P; Niwa T
Semin Nephrol; 2014 Mar; 34(2):106-17. PubMed ID: 24780467
[TBL] [Abstract][Full Text] [Related]
23. Serum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD Patients.
Paats J; Adoberg A; Arund J; Dhondt A; Fernström A; Fridolin I; Glorieux G; Leis L; Luman M; Gonzalez-Parra E; Perez-Gomez VM; Pilt K; Sanchez-Ospina D; Segelmark M; Uhlin F; Arduan Ortiz A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102247
[TBL] [Abstract][Full Text] [Related]
24. A liquid chromatography - tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism.
de Loor H; Poesen R; De Leger W; Dehaen W; Augustijns P; Evenepoel P; Meijers B
Anal Chim Acta; 2016 Sep; 936():149-56. PubMed ID: 27566350
[TBL] [Abstract][Full Text] [Related]
25. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
Henn MR; O'Brien EJ; Diao L; Feagan BG; Sandborn WJ; Huttenhower C; Wortman JR; McGovern BH; Wang-Weigand S; Lichter DI; Chafee M; Ford CB; Bernardo P; Zhao P; Simmons S; Tomlinson AD; Cook DN; Pomerantz RJ; Misra BK; Auninš JG; Trucksis M
Gastroenterology; 2021 Jan; 160(1):115-127.e30. PubMed ID: 32763240
[TBL] [Abstract][Full Text] [Related]
26. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.
Lau WL; Savoj J; Nakata MB; Vaziri ND
Clin Sci (Lond); 2018 Mar; 132(5):509-522. PubMed ID: 29523750
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of Colon-Derived Uremic Solutes.
Mair RD; Sirich TL; Plummer NS; Meyer TW
Clin J Am Soc Nephrol; 2018 Sep; 13(9):1398-1404. PubMed ID: 30087103
[TBL] [Abstract][Full Text] [Related]
28. Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction?
Dai L; Meijers BK; Bammens B; de Loor H; Schurgers LJ; Qureshi AR; Stenvinkel P; Evenepoel P
Toxins (Basel); 2020 May; 12(6):. PubMed ID: 32471179
[TBL] [Abstract][Full Text] [Related]
29. Manipulating the gut microbiome to decrease uremic toxins.
Yacoub R; Wyatt CM
Kidney Int; 2017 Mar; 91(3):521-523. PubMed ID: 28202164
[TBL] [Abstract][Full Text] [Related]
30. The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial.
Poesen R; Evenepoel P; de Loor H; Delcour JA; Courtin CM; Kuypers D; Augustijns P; Verbeke K; Meijers B
PLoS One; 2016; 11(4):e0153893. PubMed ID: 27100399
[TBL] [Abstract][Full Text] [Related]
31. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.
Itoh Y; Ezawa A; Kikuchi K; Tsuruta Y; Niwa T
Anal Bioanal Chem; 2012 Jun; 403(7):1841-50. PubMed ID: 22447217
[TBL] [Abstract][Full Text] [Related]
32. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients.
Mutsaers HA; Engelke UF; Wilmer MJ; Wetzels JF; Wevers RA; van den Heuvel LP; Hoenderop JG; Masereeuw R
PLoS One; 2013; 8(8):e71199. PubMed ID: 23936492
[TBL] [Abstract][Full Text] [Related]
33. Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.
Prokopienko AJ; Nolin TD
Expert Rev Clin Pharmacol; 2018 Jan; 11(1):71-82. PubMed ID: 28905671
[TBL] [Abstract][Full Text] [Related]
34. Protein-bound uremic toxins: new insight from clinical studies.
Liabeuf S; Drüeke TB; Massy ZA
Toxins (Basel); 2011 Jul; 3(7):911-9. PubMed ID: 22069747
[TBL] [Abstract][Full Text] [Related]
35. Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans.
Basolo A; Hohenadel M; Ang QY; Piaggi P; Heinitz S; Walter M; Walter P; Parrington S; Trinidad DD; von Schwartzenberg RJ; Turnbaugh PJ; Krakoff J
Nat Med; 2020 Apr; 26(4):589-598. PubMed ID: 32235930
[TBL] [Abstract][Full Text] [Related]
36. Protein-Bound Uremic Toxins in Hemodialysis Patients Relate to Residual Kidney Function, Are Not Influenced by Convective Transport, and Do Not Relate to Outcome.
van Gelder MK; Middel IR; Vernooij RWM; Bots ML; Verhaar MC; Masereeuw R; Grooteman MP; Nubé MJ; van den Dorpel MA; Blankestijn PJ; Rookmaaker MB; Gerritsen KGF
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32272776
[TBL] [Abstract][Full Text] [Related]
37. Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes.
Mutsaers HA; Stribos EG; Glorieux G; Vanholder R; Olinga P
Front Med (Lausanne); 2015; 2():60. PubMed ID: 26380262
[TBL] [Abstract][Full Text] [Related]
38. Role of Gut-Derived Protein-Bound Uremic Toxins in Cardiorenal Syndrome and Potential Treatment Modalities.
Lekawanvijit S
Circ J; 2015; 79(10):2088-97. PubMed ID: 26346172
[TBL] [Abstract][Full Text] [Related]
39. Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease.
Black AP; Cardozo LF; Mafra D
Ther Apher Dial; 2015 Oct; 19(5):436-40. PubMed ID: 25944654
[TBL] [Abstract][Full Text] [Related]
40. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.
Rossi M; Johnson DW; Morrison M; Pascoe EM; Coombes JS; Forbes JM; Szeto CC; McWhinney BC; Ungerer JP; Campbell KL
Clin J Am Soc Nephrol; 2016 Feb; 11(2):223-31. PubMed ID: 26772193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
